Jean-Luc Puel

This inventor holds 7 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Auris Medical Ag, National Institute of Health and Medical Research, Durect Corporation. Active years: 2009-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jean-Luc Puel. Retrieved from https://idiyas.com/inventor/jean-luc-puel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 5)

% Patents Active = 28.6

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 4.2

ph-index = 3

Forward Citations = 36(Granted Patents)

Location History:

Coumonterral, FR (2013)
Cournonterral, FR (2009 - 2021)

Company Filing History:

National Institute of Health and Medical Research

Societe De Conseils De Recherches Et D'applications Scientifiques

patents

5. 1 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 2009-2021

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10966940 - Methods for the treatment of tinnitus induced by cochlear excitotoxicity (2021-04-06),

2. 9463168 - Methods for the treatment of tinnitus induced by cochlear excitotoxicity (2016-10-11),

3. 9072662 - Methods for the treatment of tinnitus induced by cochlear excitotoxicity (2015-07-07),

4. 8507525 - Methods for the treatment of tinnitus induced by cochlear excitotoxicity (2013-08-13),

5. 8268866 - Methods for the treatment of tinnitus induced by cochlear excitotoxicity (2012-09-18),

6. 7696197 - Use of a phenothiazine derivative for preventing and/or treating hearing loss (2010-04-13),

7. 7589110 - Delivery of modulators of glutamate-mediated neurotransmission to the inner ear (2009-09-15),

Title: Inventor Spotlight: Jean-Luc Puel

Introduction

Jean-Luc Puel, an esteemed inventor based in Cournonterral, France, holds a remarkable portfolio of seven patents related to innovative treatments for auditory disorders. His work primarily focuses on developing methods for prevention and treatment of tinnitus, particularly those induced by cochlear excitotoxicity.

Latest Patents

Puel's latest patents introduce a groundbreaking pharmaceutical composition comprised of an NMDA receptor antagonist. This invention provides essential methods for treating tinnitus, a condition that may arise from various triggers such as acoustic trauma, age-related hearing loss (presbycusis), ischemia, anoxia, exposure to ototoxic medications, sudden deafness, and other cochlear excitotoxic occurrences. Additionally, these patents outline a novel screening method that incorporates electrophysiological test methods to identify effective compounds for treating and preventing tinnitus.

Career Highlights

Throughout his career, Jean-Luc Puel has collaborated with prestigious institutions such as the National Institute of Health and Medical Research (Institut National de la Santé et de la Recherche Médicale) and Auris Medical AG. His role in these organizations has enabled him to leverage his research to create impactful medical innovations aimed at improving auditory health.

Collaborations

Puel has worked alongside distinguished colleagues such as Remy Pujol and Matthieu Guitton. These collaborations have facilitated the exchange of innovative ideas and techniques, further enhancing the quality and reach of his research efforts.

Conclusion

Jean-Luc Puel continues to advance the field of audiology through his innovative inventions and research. By focusing on tinnitus treatment and prevention, he plays a crucial role in addressing a prevalent auditory condition, potentially transforming the lives of millions who suffer from this challenging disorder. Through his patents and collaborations, Puel stands out as a significant figure in the realm of medical inventions.

Profile summary based on public USPTO records.